Adirondack Trust Co. Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Adirondack Trust Co. lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 4.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 438 shares of the biopharmaceutical company’s stock after selling 22 shares during the quarter. Adirondack Trust Co.’s holdings in Regeneron Pharmaceuticals were worth $423,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Stifel Financial Corp boosted its position in shares of Regeneron Pharmaceuticals by 12.2% during the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock worth $25,537,000 after acquiring an additional 3,385 shares during the last quarter. Sierra Summit Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $1,011,000. LPL Financial LLC grew its position in shares of Regeneron Pharmaceuticals by 9.3% during the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock valued at $33,522,000 after purchasing an additional 3,479 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $749,000. Finally, Public Employees Retirement Association of Colorado lifted its position in shares of Regeneron Pharmaceuticals by 16.0% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock worth $14,118,000 after buying an additional 2,220 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 0.3 %

Regeneron Pharmaceuticals stock traded up $2.91 during mid-day trading on Tuesday, reaching $1,048.28. 83,457 shares of the company were exchanged, compared to its average volume of 466,142. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $1,052.34. The business has a fifty day moving average of $958.43 and a 200 day moving average of $938.09. The firm has a market cap of $115.51 billion, a P/E ratio of 30.88, a PEG ratio of 2.14 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). The company had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Michael S. Brown sold 1,172 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Michael S. Brown sold 1,172 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. Insiders sold a total of 61,215 shares of company stock worth $60,414,782 in the last 90 days. 7.48% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent research reports. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price objective on the stock. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. Bank of America lifted their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. Finally, UBS Group upped their price objective on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $998.09.

Read Our Latest Stock Analysis on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Recommended Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.